Anika Therapeutics (ANIK) holder discloses 1.2% passive stake update
Rhea-AI Filing Summary
Anika Therapeutics, Inc. received an updated ownership report on its common stock from Trigran Investments, Inc. and related individuals on 12/31/2025. The group reports beneficial ownership of 168,400 shares of common stock, representing 1.2% of the outstanding class.
The filing shows no sole voting or dispositive power, with all voting and dispositive authority reported as shared. Each reporting person states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Anika. They also disclaim beneficial ownership of the shares except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the Schedule 13G/A filing report for ANIK?
The Schedule 13G/A reports that Trigran Investments, Inc. and related individuals beneficially own 168,400 shares of Anika Therapeutics common stock, representing 1.2% of the class.
Who are the reporting persons in this Anika Therapeutics (ANIK) filing?
The reporting persons are Trigran Investments, Inc., Douglas T. Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon, and Steven R. Monieson.
How much of Anika Therapeutics’ stock does the Trigran group report owning?
The group reports beneficial ownership of 168,400 shares of Anika Therapeutics common stock, which equals 1.2% of the outstanding class.
Do the reporting persons seek to influence control of Anika Therapeutics (ANIK)?
No. They certify the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Anika.
Why does the filing mention ownership of 5 percent or less of a class?
Item 5 states ownership of 5 percent or less of the class, reflecting that the reported 1.2% stake is below the 5% threshold for larger blockholders.